Want to see AU:PGC full AI Analyst Report?
Top Page
Paragon Care Limited
(Sydney:PGC)
Select Model
Select Model
Rating:50Neutral
Price Target:
AU$0.14
▼(-17.65% Downside)
Action:Reiterated
Date:08/27/26
The score is primarily held back by weak financial performance: margins compressed materially and earnings turned negative, with leverage rising and free cash flow still negative. Technicals provide partial support via improving short-term momentum, but the longer-term trend remains weaker. Valuation is constrained by the negative P/E, reflecting current losses and limiting confidence in earnings-based attractiveness.
Positive Factors
Strong Revenue Growth
Sustained top-line growth indicates expanding demand for the company’s medical, scientific and clinical distribution offering. If retained, this scale can support broader customer coverage and improve the platform for future margin recovery.
Negative Factors
Severe Margin Compression
The sharp decline in gross margin and near break-even EBIT indicate that revenue growth is not currently translating into operating profitability. Persistent pricing, product-mix or cost pressure could limit earnings recovery and weaken the economics of scale.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong Revenue Growth
Sustained top-line growth indicates expanding demand for the company’s medical, scientific and clinical distribution offering. If retained, this scale can support broader customer coverage and improve the platform for future margin recovery.
Read all positive factors
Paragon Care Limited (PGC) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$231.74M
Dividend Yield2.79%
Average Volume (3M)414.54K
Price to Earnings (P/E)―
Beta (1Y)0.94
Revenue Growth1.84%
EPS Growth-178.23%
CountryAU
Employees869
SectorHealthcare
Sector Strength45
IndustryMedical - Distribution
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding1,655,305,400
10 Day Avg. Volume457,004
30 Day Avg. Volume414,538
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)0.76
Price to Sales (P/S)0.06
P/FCF Ratio-150.48
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$0.23Price Target Upside35.29% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)0.02
Revenue Forecast (FY)AU$3.79B
Paragon Care Limited Business Overview & Revenue Model
Company Description
Paragon Care Limited distributes medical equipment, devices, and consumable products in Australia, New Zealand, and Asia. The company designs, manufactures, and distributes reagent red blood cells, monoclonal blood grouping reagents, and ancillary...
How the Company Makes Money
PGC primarily makes money by selling and distributing third-party medical and scientific products (including equipment and consumables) to healthcare and laboratory customers, generating revenue from product sales. In addition to upfront equipment...
Paragon Care Limited Financial Statement Overview
Summary
Income Statement
38
Negative
Balance Sheet
55
Neutral
Cash Flow
42
Neutral
| Breakdown | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 3.68B | 3.61B | 2.97B | 307.63M | 237.62M |
| Gross Profit | 157.46M | 324.00M | 176.07M | 51.68M | 36.58M |
| EBITDA | 43.70M | 89.81M | 43.18M | 37.07M | 23.96M |
| Net Income | -16.03M | 20.57M | 8.38M | 12.80M | 6.63M |
Balance Sheet | |||||
| Total Assets | 1.37B | 1.23B | 1.13B | 448.52M | 438.44M |
| Cash, Cash Equivalents and Short-Term Investments | 23.68M | 21.90M | 19.94M | 970.00K | 46.20M |
| Total Debt | 388.90M | 296.52M | 251.83M | 122.14M | 131.26M |
| Total Liabilities | 1.08B | 915.04M | 838.97M | 196.56M | 196.31M |
| Stockholders Equity | 295.88M | 319.00M | 291.92M | 18.88M | 235.82M |
Cash Flow | |||||
| Free Cash Flow | -1.49M | -23.04M | 25.14M | -3.30M | 14.42M |
| Operating Cash Flow | 29.09M | -11.35M | 44.45M | 17.75M | 19.03M |
| Investing Cash Flow | -83.04M | -16.64M | -19.52M | -31.75M | 7.07M |
| Financing Cash Flow | 59.42M | 28.65M | -5.95M | -10.00M | -11.93M |
Paragon Care Limited Technical Analysis
Positive
0.17
Price Trends
0.13
Positive
0.14
Positive
0.17
Negative
Market Momentum
<0.01
Negative
54.83
Neutral
50.00
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:PGC, the sentiment is Positive. The current price of 0.17 is above the 20-day moving average (MA) of 0.14, above the 50-day MA of 0.13, and above the 200-day MA of 0.17, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 54.83 is Neutral, neither overbought nor oversold. The STOCH value of 50.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AU:PGC.
Paragon Care Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
69 Neutral | AU$625.21M | 86.32 | 8.45% | ― | 12.94% | -44.50% | |
61 Neutral | AU$29.86B | 42.45 | 14.34% | 1.54% | ― | ― | |
57 Neutral | AU$51.94M | 236.36 | 0.93% | ― | 18.54% | ― | |
52 Neutral | AU$10.12M | 86.67 | 3.34% | ― | 121.40% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | AU$231.74M | -15.10 | -5.34% | 2.79% | 1.84% | -178.23% | |
46 Neutral | AU$35.92M | -61.25 | -0.62% | ― | -3.05% | 86.01% |
* Healthcare Sector Average
AU:PGC
Paragon Care Limited
0.14
-0.15
-51.72%
AU:SIG
Sigma Healthcare Ltd
2.60
-0.31
-10.53%
AU:PNV
Polynovo
0.93
-0.62
-39.94%
AU:CMP
Compumedics Limited
0.26
-0.04
-13.33%
AU:EPN
Epsilon Healthcare Limited
0.03
<0.01
8.33%
AU:TRJ
Trajan Group Holdings Ltd
0.25
-0.52
-67.76%
Paragon Care Limited Corporate Events
Paragon Care Corrects Typographical Errors in Preliminary Final Report
Aug 26, 2026
Paragon Care Limited, an Australian-listed healthcare supplier, provides a wide range of medical equipment, devices, consumables, pharmaceuticals and complementary healthcare products. It also manufactures blood bank diagnostic reagents, with oper...
Paragon Care Releases FY26 Results and Highlights Cultural Acknowledgement
Aug 26, 2026
Paragon Care Limited has released its financial results for the year ended 30 June 2026 and provided an investor presentation outlining its FY26 performance. While detailed financial metrics are not disclosed in the text provided, the release sign...
Paragon Care Grants Additional Performance Rights to Director
Jul 3, 2026
Paragon Care Limited has disclosed a change in the interests of director Carmen Riley, who received a grant of 5,996,911 performance rights, lifting her total holding to 13,477,163 performance rights alongside 2,538,888 ordinary shares. The grant,...
Paragon Care Issues Nearly 6 Million Unquoted Performance Rights Under Employee Scheme
Jul 3, 2026
Paragon Care Limited has notified the market of the issue of 5,996,911 unquoted performance rights under its employee incentive scheme, effective 3 July 2026. These performance rights, which will not be quoted on the ASX, are designed to align emp...
Paragon Care Director Restructures Shareholdings Without Changing Overall Stake
Jul 1, 2026
Paragon Care Limited has reported a change in the interests of director John Walstab, detailing an internal transfer of shares between his direct and indirect holdings. The transaction involved an off-market trade of 6,000,000 ordinary shares at $...
Paragon Care Director Increases Indirect Shareholding
Jun 29, 2026
Paragon Care Limited has disclosed a change in the shareholding of director Peter Egglestone, who increased his indirect interest in the company through Panda Bear Investments Pty Ltd. His holding rose from 300,000 to 500,000 ordinary shares follo...
Paragon Care Ends Escrow-Linked Substantial Holding in Its Own Shares
Jun 2, 2026
Paragon Care Limited has notified the market that it has ceased to be a substantial holder of its own shares for disclosure purposes under Australian corporations law. The change arises because the company’s prior relevant interest, which wa...
Paragon Care flags partial Infinity recovery and affirms FY26 earnings outlook
May 31, 2026
Paragon Care Limited, a diversified healthcare supplier operating in Australia, New Zealand, and Asia, focuses on providing medical equipment, consumables, pharmaceuticals, complementary medicines, nutritional supplies, and blood bank diagnostic r...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.